GSK Announces the COiMMUNITY Initiative to Help Achieve Higher Adult Vaccination Rates in the USBusiness Wire • 06/01/23
GSK: So, just how big is the RSV opportunity? Up to $9bn, says one brokerProactive Investors • 05/15/23
The FDA Just Approved an RSV Vaccine -- and It Isn't From Moderna or PfizerThe Motley Fool • 05/11/23
US FDA Approves GSK's AREXVY, the World's First Respiratory Syncytial Virus (RSV) Vaccine for Older AdultsBusiness Wire • 05/03/23
GSK Stock Jumps After Beating Pfizer, Moderna To The RSV Vaccine Finish LineInvestors Business Daily • 05/03/23
Early ISA investors go for L&G, GSK and Fundsmith, while turning back on passive fundsProactive Investors • 04/26/23
Pharma Behemoths GSK, Roche Outplay Covid Declines To Beat Quarterly CallsInvestors Business Daily • 04/26/23